Chemical Component Summary

FormulaC6 H14 O6
Molecular Weight182.17
Isomeric SMILESC([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O

Chemical Details

Formal Charge0
Atom Count26
Chiral Atom Count4
Bond Count25
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB00742Ā 
  • approved
  • investigational
DescriptionMannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid. On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for this indication under the name BRONCHITOLĀ® by Chiesi USA Inc.[L20024]
  • D-Mannitol
  • Mannitol
  • D-(-)-Mannitol
  • (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexaol
  • (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
Brand Names
  • Bronchitol
  • TERUFLEX Blood Bag System with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell Preservative
  • TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL Red Cell Preservative
  • Osmitrol Injection 10%
  • Additive Solution Sodium Adenine Glucose Mannitol (sagm)
IndicationUsed for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances. Mannitol is also indicated as add-on maintenance therapy for improving pulmonary function in cystic fibrosis patients aged 18 and over who have passed the BRONCHITOL tolerance test (BTT). It is recommended that patients take an orally inhaled short-acting bronchodilator 5-15 minutes prior to every inhaled mannitol dose.[L20024]
  • Agents causing hyperkalemia
  • Alcohols
  • Alimentary Tract and Metabolism
  • Blood and Blood Forming Organs
  • Blood Substitutes and Perfusion Solutions
  • B05CX04
  • A06AD16
  • R05CB16
  • B05BC01
  • V04CX04
CAS number69-65-8

Drug Targets

NameTarget SequencePharmacological ActionActions
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference